Disclaimers
Cerefolin Brain Wellness™ is a targeted nutrition product for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use only under medical supervision.
* Cerefolin Brain Wellness™, formerly known and studied as CerefolinNAC®, is the same trusted and effective product that is now free from major allergens (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, sesame and soy), dyes, and colorants.
† By submitting this information, I hereby give Alfasigma USA, Inc. authorization to release, reproduce, use or distribute information about me, in original or modified form, for promotional and educational purposes in all forms of media, including print, broadcast or Internet. This information may include my medical information if I choose to submit any. I understand my information may be shared with a third party working on Alfasigma USA, Inc.’s behalf for promotional or educational purposes. I also understand that I may be contacted by this third party or Alfasigma USA, Inc. for more information.
†† This product should be taken under medical supervision, and you should consult your healthcare provider before taking this for mild cognitive impairment.
References
- Shankle WR, et al. J Alzheimer’s Dis. 2016 Oct 4;54(3):1073-1084
- Shankle WR, et al. J Aging Res Clin Prac. 2013
- Hara J, et al. Nutr Health Aging. 2015
- Alfasigma USA. Data on File. PLUS Program: Patient Survey Results 2012. USA
- Chan A, et al. J Nutr Health Aging 2008;12(4):252-61.
- de Jager CA. et al. Int J Geriatr Psychiatry. 2012 Jun:27(6):592-600.
- Merrill E, et al. Am. J. Epidemiol. 2005 Oct;162(7):644-53.
- Altern Med Rev 2000 Oct;5(5):467-71.
- de Jager CA. Neurobiol Aging 2014;35(suppl 2):535-9.
- Atkuri KR, et al. Curr Opin Pharmacol. 2007. 2007
- N-acetylcysteine. Monograph. Alt Med Rev. 2000
- Antoniades C, et al. Circulation. 2006.
- Calderón-Ospina CA, et al. CNS Neurosci Ther. 2020.
- Kimura, A.M et al. Alzheimer’s Dement. 2021.